Anti-Tumor Drugs Under Closer Scrutiny As China Confronts Widespread Misuse
Executive Summary
China has introduced new rules relating to the designation and control of cancer drugs, which are being seen by some specialists as not ideal from a clinical practice perspective but positive for novel drug development.
You may also be interested in...
South Africa Ups The Ante On COVID-19 Vaccines IP Waiver
With the COVID-19 situation spiraling out of control in India, Brazil and other parts of the world, calls for the suspension of IP protections on coronavirus vaccines are growing louder. But the R&D based pharmaceutical industry insists a waiver is not the way forward.
China Cancer Drug Misuse In Spotlight After Shocking Whistleblower Tales
Using PD-1 immuno-oncology drugs to treat post-surgery gastric cancer and prescribing unapproved targeted therapies for colon cancer are just two examples of the apparently widespread misuse of oncology drugs in China, as alleged by an oncologist at a prestigious Peking university hospital.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.